Latest Conference Articles

December 12th 2019, 12:22am

San Antonio Breast Cancer Symposium

Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

December 12th 2019, 12:16am

San Antonio Breast Cancer Symposium

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

December 11th 2019, 10:23pm

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.

December 11th 2019, 2:47am

ASH Annual Meeting and Exposition

More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.

December 11th 2019, 1:33am

ASH Annual Meeting and Exposition

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

December 11th 2019, 1:22am

ASH Annual Meeting and Exposition

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).

December 11th 2019, 1:10am

ASH Annual Meeting and Exposition

REGN1979 demonstrated antitumor activity with an acceptable safety profile in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

December 11th 2019, 12:16am

ASH Annual Meeting and Exposition

The addition of CP-0610 to ruxolitinib (Jakafi) in JAK inhibitor-naïve patients with myelofibrosis induced splenic and symptomatic responses as early as 12 weeks.

December 10th 2019, 10:55pm

ASH Annual Meeting and Exposition

The CAR T-cell therapy tisagenlecleucel (Kymriah) showed similar real-world efficacy and safety findings to that of the JULIET trial in the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma.

December 10th 2019, 10:02pm

ASH Annual Meeting and Exposition

Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.

December 10th 2019, 7:25pm

ASH Annual Meeting and Exposition

Navitoclax plus ruxolitinib (Jakafi) showed clinically meaningful spleen responses and improvements in symptoms for patients with primary or secondary myelofibrosis, following the development of resistance to frontline ruxolitinib.

December 10th 2019, 5:43pm

ASH Annual Meeting and Exposition

Ilaria Iacobucci, PhD, staff scientist, St. Jude Children’s Research Hospital, discusses the use of integrated transcriptomic and genomic sequencing in identifying prognostic constellations of driver mutations in acute myeloid leukemia and myelodysplastic syndromes.

December 10th 2019, 5:43pm

ASH Annual Meeting and Exposition

Patrick Brown, MD, chair of NCCN Guidelines for Adult and Pediatric ALL, and director of the Pediatric Leukemia Program at Sidney Kimmel Comprehensive Cancer Center, discusses the results of the randomized phase III Children’s Oncology Group Study AALL1331 trial of blinatumomab (Blincyto) versus chemotherapy as post-reinduction therapy in high- and intermediate-risk children and young adults with B-acute lymphoblastic leukemia in first relapse.

December 10th 2019, 5:32pm

ASH Annual Meeting and Exposition

Adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

December 10th 2019, 5:31pm

ASH Annual Meeting and Exposition

Maintenance treatment with CC-486, an oral formulation of azacitidine, extended median overall survival by 9.9 months compared with placebo for older patients with acute myeloid leukemia in first remission.

December 10th 2019, 5:31pm

ASH Annual Meeting and Exposition

Blinatumomab (Blincyto) as post-reinduction consolidation therapy before hematopoietic stem cell transplantation improved disease-free survival and overall survival by approximately 20% compared with intensive chemotherapy in pediatric and adolescent and young adult patients with high- or intermediate-risk of first relapse of B-cell acute lymphoblastic leukemia.

December 10th 2019, 4:50am

ASH Annual Meeting and Exposition

Enasidenib significantly improves complete remission and overall response when combined with azacitidine compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia with IDH2 mutations.

December 10th 2019, 4:02am

ASH Annual Meeting and Exposition

Treatment with the anti-CD19 CAR T-cell therapy KTE-X19 elicited a complete remission rate of 67% and an objective response rate of 93% for patients with relapsed/refractory mantle cell lymphoma.

December 10th 2019, 2:08am

ASH Annual Meeting and Exposition

Patients with relapsed/refractory chronic lymphocytic leukemia had ongoing benefits 42 months after starting treatment with the BTK inhibitor acalabrutinib.

December 10th 2019, 1:18am

ASH Annual Meeting and Exposition

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.